OUR MISSION
To useourproprietaryLDL technologytocreatenewchemotherapeuticsthat selectivelytargettumorsandtherebyimprovetolerabilityandefficacyof knownmoleculesaswellasenablenovelones.
OUR MISSION
To use our proprietary LDL technology to create new chemotherapeutics that selectively target tumors and thereby improve tolerability and efficacy of known molecules as well as enable novel ones.
Cloaked Therapeutics, LLC is a private biopharmaceutical limited liability company registered in Delaware and located near Oxford, Mississippi. Cloaked was formed in 2014 to commercially develop, under exclusive license, proprietary TumorSelect® technology discovered by Veiled Therapeutics, LLC.
The company’s proprietary TumorSelect® technology selectively delivers active anticancer agents into tumor cells. Pseudo-LDL particles containing novel prodrugs of clinically approved chemotherapeutic agents are used to improve the selective uptake of cytotoxics by tumors in order to improve efficacy and reduce toxicity. This technology is well established both preclinically and clinically.
Cloaked has used TumorSelect® to create an exciting proof-of-concept lead program with an advanced delivery system for paclitaxel that promises to improve both its efficacy and tolerability when compared with standard Cremophor® as well as newer Abraxane® formulations.
TECHNOLOGY
TumorSelect® mechanism of action has potential indications for enhanced safety and efficacy of therapy by selective delivery to tumor tissues including the cancers:
- Breast
- Colorectal
- Gastric
- Glioblastoma
- Leukemia
- Melanoma
- Non-small cell lung
- Ovarian
- Pancreatic
- Prostate
MANAGEMENT
Each of the founding technical members of Cloaked Therapeutics is a recognized and experienced leader in drug discovery and development.